4539 Stock Overview
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Nippon Chemiphar Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,612.00 |
| 52 Week High | JP¥2,112.00 |
| 52 Week Low | JP¥1,550.00 |
| Beta | 0.16 |
| 1 Month Change | -5.18% |
| 3 Month Change | 0.31% |
| 1 Year Change | -9.84% |
| 3 Year Change | -32.58% |
| 5 Year Change | -44.39% |
| Change since IPO | -83.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4539 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.1% | 2.7% | 1.8% |
| 1Y | -9.8% | 4.7% | 31.0% |
Return vs Industry: 4539 underperformed the JP Pharmaceuticals industry which returned 4.7% over the past year.
Return vs Market: 4539 underperformed the JP Market which returned 31% over the past year.
Price Volatility
| 4539 volatility | |
|---|---|
| 4539 Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4539 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4539's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 872 | Kazushiro Yamaguchi | www.chemiphar.co.jp |
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development.
Nippon Chemiphar Co., Ltd. Fundamentals Summary
| 4539 fundamental statistics | |
|---|---|
| Market cap | JP¥5.89b |
| Earnings (TTM) | -JP¥241.00m |
| Revenue (TTM) | JP¥30.61b |
0.2x
P/S Ratio-24.4x
P/E RatioIs 4539 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4539 income statement (TTM) | |
|---|---|
| Revenue | JP¥30.61b |
| Cost of Revenue | JP¥22.93b |
| Gross Profit | JP¥7.68b |
| Other Expenses | JP¥7.92b |
| Earnings | -JP¥241.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -65.99 |
| Gross Margin | 25.09% |
| Net Profit Margin | -0.79% |
| Debt/Equity Ratio | 93.0% |
How did 4539 perform over the long term?
See historical performance and comparison